P3-090: Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)  by Grossi, Francesco et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S717
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
effective in pts progressing on G (Viswanathan A et al, Lung Cancer 
2005). Aim of this study was the evaluation of response and time to 
progression (TTP) in advanced NSCLC pts treated with G after failure 
of E.
Methods: Pts received G 250 mg/day after disease progression (PD) 
with E 150 mg/day. Pts accrual was stopped on August 2006 after the 
approval of E for use in Italy and the consequent closure of the G com-
passionate-use program. 
Results: From May 2005 to August 2006, 15 pts were enrolled. Median 
age 65 years (50-85); males= 14 pts (93%); never/former smokers= 
4/10 pts (26/67%); adenocarcinoma= 10 pts (67%); PS 0/1= 5/10 pts 
(33/67%); in 2 pts (13%) E was administered as ﬁrst-line therapy, 8 pts 
(53%) received 2 prior lines of chemotherapy (CT) and 3 pts (20%) 
received CT between E and G. One patient (7%) had a partial response 
(PR) and 5 pts (33%) had disease stabilization (SD) with E; with G no 
PR and 6 SD (40%) were obtained. Five out of 6 RP/SD pts with E, had 
SD with G; 8 out of 9 PD pts with E, had PD with G; 1 SD patient with 
E, progressed with G and 1 vice versa. TTP in RP/SD pts was 7.2 and 
3.4 months for E and G respectively; in PD pts TTP was 1.7 and 1.6 for 
E and G respectively.
Conclusions: Our data suggest that there is a beneﬁt with G in pts who 
had RP/SD with E and that is associated with a good TTP. Conversely 
G is not recommended in pts that immediately progressed after E. An 
analysis of the role of mutational status and other biomarkers in pre-
dicting clinical outcome is currently underway.
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Background: One retrospective study (Hotta K, Ann Oncol 2005), in-
vestigating the prognosis of patients (pts) obtaining SD as best response 
with G treatment, has demonstrated that both progression-free survival 
(PFS) and survival (S) were signiﬁcantly longer than those in pts with 
progressive disease (PD). The aim of this retrospective study was to 
compare the PFS and S outcome in pts with advanced NSCLC who 
achieved SD or partial response (PR) after treatment with E or G.
Methods: Pooled data from 62 pts, entered into an expanded access 
program of E (n=31) and a compassionate-use program of G (n=31), 
were retrospectively analyzed. E and G were given orally at 150 and 
250 mg per day respectively and were continued until disease progres-
sion, development of unacceptable toxicity or patient’s refusal.
Results: Pts characteristics: median age 69 years (42-85); females= 
21 pts (34%); never/former smokers= 16/38 pts (26/61%); adenocar-
cinoma/BAC= 35/10 pts (56/16%); PS 0/1= 18/38 pts (29/61%). In 16 
pts (26%) E or G were given as ﬁrst-line therapy; 21 pts (34%) had 
received ≥2 prior lines of chemotherapy. Six pts (10%) achieved a PR 
and 18 pts (29%) obtained SD. TTP and OS in pts obtaining PR and 
SD were comparable: 7 vs 5.5 and 9.7 vs 9.1 months respectively. In 
progressing pts median TTP and OS were 1.7 and 3.7 months. No dif-
ference in response, TTP and S between E and G were demonstrated.
Conclusions: Our ﬁndings indicate the importance of achieving disease 
control with both E and G treatment. Pts obtaining SD with E or G had 
a similar PFS and S compared with those having PR. 
An analysis of the role of mutational status and other biomarkers in 
predicting clinical outcome is currently underway.
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Background: BIBF 1120 is a highly potent, orally bioavailable triple 
angiokinase inhibitor (VEGFRs, PDGRs, FGFRs) that suppresses tu-
mor growth through mechanisms inhibiting tumor neovascularization. 
Pemetrexed is an antifolate agent that inhibits de novo DNA synthesis 
pathways and has demonstrated clinical beneﬁt in advanced or meta-
static NSCLC after prior ﬁrst line chemotherapy. 
This Phase I, open-label dose escalation study investigated the combi-
nation of BIBF 1120 together with pemetrexed in previously treated pa-
tients with recurrent advanced stage NSCLC. The potential additive or 
synergistic effects of novel therapeutic regimens may make combina-
tions of these agents particularly attractive for the treatment of patients 
with recurrent NSCLC compared to a single agent alone.
The primary objectives of this trial were to determine the safety, toler-
ability, and maximum tolerated dose (MTD) of BIBF 1120 in combina-
tion with pemetrexed.
Methods: Patients with advanced stage NSCLC, PS 0-1, previously 
treated with one ﬁrst line platinum-based chemotherapy regimen were 
eligible for this trial. The trial was an open label, dose escalation design 
with BIBF 1120 at a starting dose of 100 mg bid, taken on days 2-21, 
combined with standard dose pemetrexed (500 mg/m2) given as a 10 
minute intravenous infusion on day 1 of a 21 day cycle. Patients could 
be treated for a minimum of four and a maximum of six cycles of 
the combination therapy, with an option of BIBF 1120 monotherapy 
following the completion of the combination stage. BIBF 1120 was 
escalated at doses of 50 mg per cohort until the MTD dose was deter-
mined. The MTD was deﬁned as the dose of BIBF 1120 which was one 
dose cohort below the dose at which two or more out of six patients 
experienced dose limiting toxicity (DLT) in the ﬁrst treatment cycle. 
Tumor assessments were performed at screening and after every second 
treatment cycle according to RECIST.
Results: Twenty-six patients (13 male, 13 female) in total and 12 at 
the MTD were treated in this study. The MTD dose of BIBF 1120 was 
determined to be 200 mg bid in combination with standard dose peme-
trexed. Generally the combination of BIBF 1120 and pemetrexed was 
well tolerated. A total of 17 DLT events (CTCAE Grade 3) occurred 
in the ﬁrst treatment cycle for all doses, including elevations in liver 
enzymes (3/17), fatigue (4/17), anorexia (2/17) and gastrointestinal 
disorders (6/17). These events resolved following discontinuation of 
the study medication. No Grade 4 events occurred in the study. Best 
responses by RECIST included (20 evaluable for response) 1 complete 
